Empowering physicians with Advanced Genetic Sequencing to improve cancer patient management.

OnkoSight AdvancedTM, available at GenPath, a business unit of BioReference®, is a next-generation sequencing (NGS) assay that enables cutting edge DNA mutational profiling of tumor samples. OnkoSight AdvancedTM focuses on only actionable mutations in common cancers. This targeted approach helps personalize patient treatment and management while greatly reducing the number of unclear variants that often occur in the results of broader NGS panels.

Genes included on OnkoSight AdvancedTM NGS panels are those with clear therapeutic, diagnostic, or prognostic value and those for which there are late-stage clinical trials available. National guidelines-recommended genes are included on each tumor-specific panel.

Critical genomic biomarkers relevant to immunotherapy; Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) are also reported with every OnkoSight AdvancedTM analysis.


Entire exonic coding regions and selected introns are broadly covered among genes targeted for analysis. Coverage of whole exonic coding regions represents an improvement over targeted hotspot approaches, and minimizes the risk of potential false negatives due to lack of coverage across clinically relevant genomic loci.


To learn more about our OnkoSight Advanced™ testing, please visit our GenPath website.